Search Results - therapeutic

64 Results Sort By:
PERILIPIN-1 SPECIFIC T CELLS FOR SELECTIVE FAT TARGETING
Researchers at UCSF and CZ Biohub SF have described cells expressing a heterologous T-cell receptor, that binds to an adipose-specific protein perilipin 1 peptide complex, thereby enabling selecting targeting of fat cells. T cell tolerance is enforced in the thymus through the expression of a wide array of self proteins called tissue-specific antigens...
Published: 10/23/2025   |   Inventor(s): Mark Anderson, Irina Proekt, Joseph DeRisi
Keywords(s): Autoantibody, Autoimmune, Therapeutic
Category(s): Technology Classifications > Biology
ENGINEERED ANTIBODY CONSTANT REGION POLYPEPTIDES AND RELATED METHODS
Researchers at Stanford have identified amino acid modifications in the IgG Fc region which extend its therapeutic half-life and improve its in vivo receptor binding. Biologic therapeutics, including therapeutic antibodies, that incorporate the Fc domain of antibodies are an important and growing class of drugs that have revolutionized the treatment...
Published: 10/23/2025   |   Inventor(s): Varun Shanker, Soohyun Kim, Peter Kim
Keywords(s): Antibody, Fc Domain, Therapeutic
Category(s): Technology Classifications > Biology
OPTIMIZING CANCER CHEMOTHERAPY WITH THE GUT MICROBIOME
Researchers at UCSF have developed a novel innovation in harnessing the gut microbiome to alleviate severe side effects of chemotherapy. Dose-limiting toxicities remain a significant barrier in the advancement of drug therapies, particularly in oncology. Although decades of pharmacogenomic research have identified specific human genetic variants that...
Published: 10/23/2025   |   Inventor(s): Peter Turnbaugh, Chloe Atreya, Kidder Wesley, Kai Trepka
Keywords(s): Cancer, Diagnostics, Therapeutic
Category(s): Technology Classifications > Biology
ANTIBODY DIRECTED THERAPY TO PREVENT AND TREAT CHRONIC LUNG DISEASE OF INFANCY
Researchers at Stanford and CZ Biohub SF have developed a novel antibody mediated strategy for the treatment of pediatric chronic lung diseases. Over 10% of infants worldwide are born prematurely, many of whom develop bronchopulmonary dysplasia (BPD), a serious lung disease with many comorbities. In the U.S., around 10,000 infants are diagnosed with...
Published: 10/23/2025   |   Inventor(s): David Cornfield, Cristina Alvira, Stephen Quake, Carsten Knutsen
Keywords(s): Antibody, Therapeutic
Category(s): Technology Classifications > Biology
Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers
Abstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Ira Pastan
Keywords(s): ANTIBODY, Immunotherapy, MESOTHELIN, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents
Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...
Published: 5/14/2025   |   Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho
Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington
Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent
Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...
Published: 5/14/2025   |   Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho
Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain
Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD),...
Published: 4/22/2025   |   Inventor(s): Terrence Burke, Wen-Jian Qian, Kyung Lee, Jung-Eun Park, James Kelley
Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
1 2 3 4 5 6 7